Companies: Merck & Co., Novo Nordisk
Drugs: CagriSema, Keytruda, pembrolizumab, tirzepatide, Zepbound
MSD MRK NVO
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
100% citation coverage1 peer-reviewed sources
Novo Nordisk’s CagriSema Phase 3 program produced 22.7% mean weight loss in REDEFINE 1, reinforcing the program as a major obesity catalyst. This plan frames the results, the next clinical milestones, and why BD and investor teams should track them.
Intelligence Snapshot
Executive Summary
CagriSema achieved 22.7% mean weight loss at 68 weeks in REDEFINE 1, establishing a strong placebo-controlled efficacy signal in obesity.
Key Insights
-
A Phase 3 trial (NCT07564414) is recruiting to evaluate two doses of CagriSema versus…
A Phase 3 trial (NCT07564414) is recruiting to evaluate two doses of CagriSema versus semaglutide in obesity with or without type 2 diabetes .
-
REDEFINE 3 (NCT05669755), a Phase 3 cardiovascular outcomes trial, is active but not…
REDEFINE 3 (NCT05669755), a Phase 3 cardiovascular outcomes trial, is active but not recruiting, and a Phase 3 pediatric type 2 diabetes trial (NCT07282613) is not yet recruiting.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Loading intelligence…
Loading intelligence…
Loading intelligence…
Quick Answer
CagriSema achieved 22.7% mean weight loss at 68 weeks in REDEFINE 1, establishing a strong placebo-controlled efficacy signal in obesity.
Key Questions
- What were the results of the Novo Nordisk CagriSema trial?
- What are the next clinical milestones for CagriSema?
- What is the development status of CagriSema?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CagriSema.
Unlock full calendar →Merck & Co. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents12 sections
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
Novo Nordisk's CagriSema Phase 3 program produced 22.7% mean weight loss in REDEFINE 1, reinforcing the program as a major obesity catalyst. This readout frames the clinical results, the next trial milestones, and why BD and investor teams should track them.
IntelligenceRegulatory Impact
EMA decisions frame this story. Regulatory relevance is high for oncology, with CagriSema and Keytruda most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
REDEFINE 1 establishes CagriSema's obesity efficacy signal
The REDEFINE 1 Phase 3 trial found that CagriSema resulted in 22.7% mean weight reduction at 68 weeks in adults with overweight or obesity, compared to 2.3% in the placebo group. This placebo-controlled result anchors Novo Nordisk's obesity franchise and positions CagriSema as a clinical candidate worthy of BD diligence and investor catalyst tracking.
For business development and investor teams, the question now centers on what happens next. Multiple Phase 3 trials remain active or recruiting across obesity, type 2 diabetes, cardiovascular disease, and muscle health. Each represents a potential inflection point for partnership discussions, regulatory strategy, and valuation models.
IntelligenceCompetitive Intelligence
Merck & Co. and Novo Nordisk are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
Key Takeaways
- CagriSema achieved 22.7% mean weight loss at 68 weeks in REDEFINE 1, establishing a strong placebo-controlled efficacy signal in obesity.
- A Phase 3 trial (NCT07564414) is recruiting to evaluate two doses of CagriSema versus semaglutide in obesity with or without type 2 diabetes.
- REDEFINE 3 (NCT05669755), a Phase 3 cardiovascular outcomes trial, is active but not recruiting, and a Phase 3 pediatric type 2 diabetes trial (NCT07282613) is not yet recruiting.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for oncology. Expect implications for pricing, access, and launch sequencing.
Active and upcoming trials shape the near-term catalyst calendar
NCT07564414 is a Phase 3 trial comparing two doses of CagriSema with semaglutide in people living with obesity with or without type 2 diabetes and is currently recruiting. This study will provide clinical context for CagriSema's positioning relative to an established standard of care in the obesity setting.
REDEFINE 3 (NCT05669755), a Phase 3 cardiovascular outcomes trial, is active but not recruiting. A separate Phase 3 trial (NCT07282613) is evaluating CagriSema in children and adolescents with type 2 diabetes and is not yet recruiting.
Additionally, a Phase 1 study (NCT07527195) is recruiting to examine the effect of CagriSema, cagrilintide, and semaglutide on muscle health. These trials collectively represent the development roadmap that will drive investor and BD attention over the next 12 to 24 months.
IntelligenceStrategic Takeaways
CagriSema achieved 22.7% mean weight loss at 68 weeks in REDEFINE 1, establishing a strong placebo-controlled efficacy signal in obesity. A Phase 3 trial (NCT07564414) is recruiting to evaluate two doses of CagriSema versus semaglutide in obesity with or without type 2 diabetes . REDEFINE 3 (NCT05669755), a Phase 3 cardiovascular outcomes trial, is active but not recruiting, and a Phase 3 pediatric type 2 diabetes tr
What this means for BD and investor tracking
The REDEFINE 1 readout confirms CagriSema as a viable obesity clinical candidate. For investors modeling peak sales and partnership valuations, the key variables are the outcomes of the semaglutide-comparison trial and the cardiovascular outcomes study. For BD teams evaluating licensing, co-promotion, or acquisition opportunities, the timing and results of these catalysts will inform partnership discussions and regulatory strategy.
Renal or hepatic impairment does not affect the pharmacokinetics, safety, or tolerability of subcutaneous cagrilintide, which may support label breadth and patient access in populations with comorbidities. This detail is relevant to commercial positioning and real-world use.
IntelligenceEvidence Quality
Grounded in 1 peer-reviewed source.
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | RECRUITING | PHASE3 | Novo Nordisk A/S |
| NCT07282613 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | NOT_YET_RECRUITING | PHASE3 | Novo Nordisk A/S |
| NCT05669755 | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | ACTIVE_NOT_RECRUITING | PHASE3 | Novo Nordisk A/S |
| NCT06289504 | A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight | COMPLETED | PHASE1 | Novo Nordisk A/S |
| NCT07527195 | Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | RECRUITING | PHASE1 | Novo Nordisk A/S |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Cancer Institute (NCI) | oncology | 2 |
| National Institute of Dental and Craniofacial Research (NIDCR) | oncology | 1 |
| Janssen Research & Development, LLC | oncology | 1 |
| Arsenal Biosciences, Inc. | oncology | 1 |
| Regina Elena Cancer Institute | oncology | 1 |
| Aragon Pharmaceuticals, Inc. | oncology | 1 |
Timeline
- Recruiting trial NCT07564414 (PHASE3)
- Not_Yet_Recruiting trial NCT07282613 (PHASE3)
- Active_Not_Recruiting trial NCT05669755 (PHASE3)
- Recruiting trial NCT07527195 (PHASE1)
- Recruiting trial NCT07353957 (PHASE2)
Frequently Asked Questions
What were the results of the Novo Nordisk CagriSema trial?
In the REDEFINE 1 Phase 3 trial, CagriSema resulted in 22.7% mean weight reduction at 68 weeks in adults with overweight or obesity, compared to 2.3% with placebo.
What are the next clinical milestones for CagriSema?
Key upcoming catalysts include a Phase 3 obesity trial comparing CagriSema to semaglutide (NCT07564414, recruiting), a cardiovascular outcomes trial (NCT05669755, active but not recruiting), and a pediatric type 2 diabetes trial (NCT07282613, not yet recruiting).
What is the development status of CagriSema?
CagriSema is in Phase 3 development across multiple indications. REDEFINE 1 in obesity has completed enrollment and reported results. No regulatory approval or filing has been announced to date.
Related profiles
Related coverage
- Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact
- Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
- Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About oncology
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow CagriSema developments
FDA oncology alerts and CagriSema pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 91/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- RYBREVANT® Access and Reimbursement Guide Overview — Explore key insights on RYBREVANT® reimbursement and access strategies for NSCLC treatment.…
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…